The firm had been notified by the exchange in August that it failed to meet a listing requirement calling for a minimum $1 bid price on its stock.
The cell-based diagnostics firm sold a total of 2.76 million shares, including 360,000 shares to the offering's underwriter.
The cell-based cancer diagnostics firm said in an SEC filing that it plans to offer 2 million shares of its common stock at between $8 and $10 per share.
Amid a flat month for the index, some firms saw large swings in their stock price. Natera led the gainers, while NantHealth led the decliners.
The molecular diagnostics firm was told on Wednesday that it is again in compliance with a rule calling for a $1 minimum bid on its share price.
Its technology called CELx uses a patient's tumor cells to identify abnormal cellular activity driving their cancer and the most appropriate therapy.
The firm's market value fell below the minimum $35 million level to remain listed on the Nasdaq. HTG has until Jan 29, 2018 to regain compliance.
The Index was up about 4 percent month over month and outpaced the Dow Jones Industrial Average and the Nasdaq Composite, but trailed the Nasdaq Biotechnology index.
The firm established an "at-the-market" program to offer up to $21.2 million of its common stock from time to time. Proceeds will be used for business operations.
Nasdaq told the firm on Tuesday that its shares failed to maintain a minimum bid price of $1 per share for at least 30 consecutive trading days.